Novel Tricyclic Pyroglutamide Derivatives as Potent RORγt Inverse Agonists Identified using a Virtual Screening Approach.

导出 OA

翻译打印收藏纠错

作者： Qingjie,Liu ^[1] ; Douglas G,Batt ^[1] ; Carolyn A,Weigelt ^[1] ; Shiuhang,Yip ^[1] ; Dauh-Rurng,Wu ^[1] ; Max,Ruzanov ^[1] ; John S,Sack ^[1] ; Jinhong,Wang ^[1] ; Melissa,Yarde ^[1] ; Sha,Li ^[1] ; David J,Shuster ^[1] ; Jenny H,Xie ^[1] ; Tara,Sherry ^[1] ; Mary T,Obermeier ^[1] ; Aberra,Fura ^[1] ; Kevin,Stefanski ^[1] ; Georgia,Cornelius ^[1] ; Purnima,Khandelwal ^[1] ; Joseph A,Tino ^[1] ; John E,Macor ^[1] ; Luisa,Salter-Cid ^[1] ; Rex,Denton ^[1] ; Qihong,Zhao ^[1] ; T G Murali,Dhar ^[1]

作者单位： Research and Early Development, Bristol Myers Squibb Company, Princeton, New Jersey 08540-4000, United States. ^[1]

DOI 10.1021/acsmedchemlett.0c00496

PMID 33335675

发布时间 2021-12-11

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览3

ACS medicinal chemistry letters

2020年11卷12期

2510-2518页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Novel Tricyclic Pyroglutamide Derivatives as Potent RORγt Inverse Agonists Identified using a Virtual Screening Approach.

ACS medicinal chemistry letters

相似文献

ACS medicinal chemistry letters

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Novel Tricyclic Pyroglutamide Derivatives as Potent RORγt Inverse Agonists Identified using a Virtual Screening Approach.

ACS medicinal chemistry letters

相似文献

ACS medicinal chemistry letters

相关期刊

检索历史清除